Brain Cancer Trial, Recruiting NCT06933199 Sponsor: University Hospital Ostrava Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT06933199
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People whose general health and ability to carry out daily activities meets a minimum functional threshold (known as a Karnofsky Performance Status score of 60 or above — confirm with trial site if unsure what this means for a specific situation)
  • People whose cancer has been confirmed through a tissue sample (biopsy or similar laboratory testing)
  • People whose MRI scan shows signs of brain metastases (cancer that has spread to the brain)
  • People who have one brain metastasis that doctors have recommended for surgical removal, and any other brain metastases that are suitable for a focused radiation treatment called stereotactic radiotherapy
  • People whose main target brain metastasis measures between 1 cm and 7 cm at its longest point on a specific type of MRI scan (T1 post-contrast imaging)

Who may not be able to join:

  • People whose cancer is a blood cancer (such as leukaemia or lymphoma)
  • People with small-cell lung carcinoma (a specific type of lung cancer)
  • People experiencing a sudden, severe neurological emergency requiring immediate brain surgery
  • People who have previously had whole-brain radiotherapy
  • People who have previously had stereotactic radiotherapy directed at the brain metastasis being targeted in this trial
  • People who are pregnant
  • People for whom surgery on the target brain metastasis cannot be performed within 7 days after the pre-surgical radiation treatment used in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jakub Cvek, Assoc.Prof., MD, Ing, PhD, MBA, University Hospital Ostrava

Phone: 0042059737

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital Ostrava
Registry
ClinicalTrials.gov
Start date
1 May 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇿 Czechia

Primary endpoints

Acute Toxicity; Quality of Life Questionnaire (FACT-Br/EORTC QLQ-C30); Quality of Life Questionnaire (EORTC QLQ-BN20)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov